Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1829 Target Snapshot

Histone deacetylase 3 · SINGLE PROTEIN · Homo sapiens

3,447Compounds
762Assays
11Approved Drugs
4,012.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Histone deacetylase 3 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O15379. Start with cancer, then reuse UniProt O15379 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt O15379 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
cancer

Histone deacetylase 3 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include MOCETINOSTAT, VORINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 3 as ChEMBL target CHEMBL1829, mapped to UniProt O15379. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1829
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15379
Histone deacetylase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Histone deacetylase 3 is the right protein anchor across sources, using UniProt O15379 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHistone deacetylase 3
UniProt AccessionO15379
Component TypeProtein
Sequence Length428 aa

Histone deacetylase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Histone deacetylase 3, mapped to UniProt O15379. Sequence length is 428 aa.

Mapped IDO15379
Review nameHistone deacetylase 3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Histone deacetylase 3 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOCETINOSTAT
Linked drugVORINOSTAT
Approved-linked Approved
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOCETINOSTAT
Linked drugVORINOSTAT
Approved-linked Approved
Cutaneous T-cell lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVORINOSTAT
Approved-linked Approved
T-cell non-Hodgkin lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVORINOSTAT
Late clinical Phase III
acute myeloid leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOCETINOSTAT
Linked drugVORINOSTAT
Late clinical Phase III
lung cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOCETINOSTAT
Linked drugVORINOSTAT
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include MOCETINOSTAT, VORINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

11
Approved
10
Phase III
15
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC503,894.0
KI114.0
EC502.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5413269 10.4 Ki 0.04 Preclinical
CHEMBL4860000 10.22 IC50 0.06 Preclinical
CHEMBL4862152 10.1 IC50 0.08 Preclinical
CHEMBL4641682 10.06 IC50 0.087 Preclinical
CHEMBL4649205 10.03 IC50 0.093 Preclinical
CHEMBL483254 10.0 Ki 0.1 Approved
CHEMBL4861467 10.0 IC50 0.1 Preclinical
CHEMBL4878197 9.89 IC50 0.13 Preclinical
CHEMBL99 9.85 Ki 0.14 Preclinical
CHEMBL343448 9.82 Ki 0.15 Approved
Distribution

pChEMBL Value Distribution

213
5.0
413
5.5
498
6.0
560
6.5
436
7.0
291
7.5
204
8.0
158
8.5
93
9.0
23
9.5
pChEMBL
Approved Drugs

Approved Drugs

GIVINOSTAT
CHEMBL1213492
Approved 2024
PANOBINOSTAT
CHEMBL483254
Approved 2015
BELINOSTAT
CHEMBL408513
Approved 2014
ROMIDEPSIN
CHEMBL343448
Approved 2009
BENDAMUSTINE
CHEMBL487253
Approved 2008
VORINOSTAT
CHEMBL98
Approved 2006
Assay Landscape

Assay Landscape

762
Total Assays
2,607
Tested Compounds
3
Assay Types
Binding — 756 assays, 2,607 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 568 2,056 6.7
cell-based format 158 452 6.7
assay format 25 63 6.3
subcellular format 4 34 6.5
organism-based format 1 2 8.3
ADME — 5 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 6 6.8
cell-based format 1 0
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine